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Abstract
Background Mucopolysaccharidosis type IIIB (MPS IIIB) is
a rare genetic disorder in which the deficiency of the lysosom-
al enzyme N-acetyl-α-glucosaminidase (NAGLU) results in
the accumulation of heparan sulfate (HS), leading to progres-
sive neurocognitive deterioration. In MPS IIIB a wide spec-
trum of disease severity is seen. Due to a large allelic hetero-
geneity, establishing genotype-phenotype correlations is diffi-
cult. However, reliable prediction of the natural course of the
disease is needed, in particular for the assessment of the effi-
cacy of potential therapies.
Methods To identify markers that correlate with disease se-
verity, all Dutch patients diagnosed with MPS IIIB were
characterised as either rapid (RP; classical, severe phenotype)
or slow progressors (SP; non-classical, less severe phenotype),
based on clinical data. NAGLU activity and HS levels were
measured in patients’ fibroblasts after culturing at different
temperatures.
Results A small, though significant difference in NAGLU ac-
tivity was measured between RP and SP patients after cultur-
ing at 37 °C (p<0.01). Culturing at 30 °C resulted in more
pronounced and significantly higher NAGLU activity levels
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in SP patients (p < 0.001) with a NAGLU activity of
0.58 nmol.mg-1.hr-1 calculated to be the optimal cut-off value
to distinguish between the groups (sensitivity and specificity
100 %). A lower capacity of patients’ fibroblasts to increase
NAGLU activity at 30 °C could significantly predict for the
loss of several disease specific functions.
Conclusion NAGLU activity in fibroblasts cultured at 30 °C
can be used to discriminate between RP and SP MPS IIIB
patients and the capacity of cells to increase NAGLU activity
at lower temperatures correlates with disease symptoms.
Introduction
Mucopolysaccharidosis type III (MPS III or Sanfilippo dis-
ease) is a rare autosomal recessive lysosomal storage disorder
in which the deficiency of one of four enzymes involved in the
degradation of heparan sulfate (HS) leads to the accumulation
of this specific glycosaminoglycan (GAG) (Muenzer 2011).
The reported birth incidence for MPS III ranges from 1.52 to
1.89 per 100,000 newborns (Poorthuis et al 1999; Baehner et
al 2005). Based on the deficient enzyme, four different MPS
III subtypes are distinguished referred to asMPS IIIA (OMIM
#252900), B (OMIM #252920), C (OMIM #252930) and D
(OMIM #252940) (Muenzer 2011). Clinically these subtypes
are indistinguishable.
The clinical course of the disease is generally divided into
three stages. After a symptom-free interval, patients normally
present between the age of 1 and 4 years with a delay in
cognitive development, especially in the development of
speech and language skills. The second phase of the disease
starts at the age of 3 to 4 years and is marked by a progressive
intellectual decline which is accompanied by behavioral and
sleeping problems. Eventually, the third phase sets in, charac-
terized by the regression of motor functions. Patients lose the
ability to walk independently, become wheelchair bound and
fully care dependent. Patients with this rapidly progressing
classical phenotype (rapid progressors, RP) usually die at the
end of the second or in the beginning of the third decade of life
(Valstar et al 2008). However, in recent years it has been
recognized that MPS III is characterized by a much broader
spectrum of disease progression and severity. Survival well
into adulthood has been reported and patients may show a
stable developmental impairment for many years (Moog et
al 2007; Valstar et al 2010a, b). In the Netherlands, most
patients with MPS IIIB display this slowly progressing atten-
uated phenotype (slow progressors, SP) (Valstar et al 2010a).
MPS IIIB is caused by a deficiency of the enzyme N-
acetyl-α-glucosaminidase (EC 3.2.1.50) which is responsible
for the hydrolysis of the α, 1→ 4 linkage between N-
acetylglucosamine and the adjacent glucuronic or iduronic acid
residue (Esko et al 2009). The gene encoding for NAGLU is
localized on chromosome 17q21.1 (Zhao et al 1996) and over
100 mutations in the NAGLU gene (HGNC: 7632) have been
identified (van de Kamp et al 1976; Beesley et al 1998, 2004,
2005; Schmidtchen et al 1998; Zhao et al 1998; Bunge et al
1999; Weber et al 1999; Esposito et al 2000; Tessitore et al
2000; Emre et al 2002; Chinen et al 2005; Champion et al
2010; Valstar et al 2010a; Ouesleti et al 2011; Selmer et al
2012; Tang et al 2013). Due to this large allelic heterogeneity,
establishing a genotype-phenotype correlation is difficult.
Although there is no disease modifying treatment available
for MPS IIIB, several promising therapies are currently under
investigation. A trial on intravenous enzyme replacement ther-
apy (ERT) has recently been initiated (clinicaltrials.gov iden-
tifier: NCT02324049) and a study on intrathecal ERT is in a
preclinical phase for MPS IIIB (http://www.bmrn.com/
pipeline/index.php). The latter approach is already in a phase
2b study for MPS IIIA (clinicaltrials.gov identifiers:
NCT01299727 and NCT02060526). Intracerebral gene
therapy has been developed for MPS IIIB and is now in a
phase 1/2 study (ISRCTN identifier: ISRCTN19853672).
Furthermore, the efficacy of high dose oral genistein, which
reduces the accumulation of HS inMPS III mice (Malinowska
et al 2009, 2010) is being investigated in patients with all MPS
III subtypes (EudraCT number: 2013-001479-18).
In order to properly target a disease modifying therapy, and to
allow accurate evaluation of potential clinical benefits, it is es-
sential to reliably predict the natural course of the disease for
each individual patient at an early stage. We therefore aimed to
identify markers that correlate with disease severity in MPS IIIB
patients. We analyzed NAGLU activity and levels of stored HS
in fibroblasts of MPS IIIB patients after culturing cells at differ-
ent temperatures and correlated this to their clinical phenotype.
Material and methods
Patients
All Dutch patients diagnosed with MPS IIIB of whom cul-
tured skin fibroblasts were available and essential clinical data
could be retrieved from medical records, were included in this
study. Data was collected on survival and the age at which the
ability to speak (defined as: to verbally communicate inten-
tionally with meaningful words) and to walk (defined as: to
walk independently without any assistance) was lost. Based
on the essential clinical data set, patients were divided into two
groups by a clinician experienced in the diagnosis and treat-
ment of lysosomal storage disorders, including MPS IIIB
(FAW). The rapid progressor group (RP) consisted of patients
with a classical, severe form of the disease and the slow
progressor group (SP) of patients with a non-classical, less
severe phenotype.
Informed consent for the use of patient data and fibroblasts
was obtained from parents or legal representatives for all
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patients. This study was submitted to the Medical Ethical
Review Board of the Academic Medical Center in
Amsterdam who declared that ethical approval was not nec-
essary because of the observational nature of the study.
Mutation analysis
Mutation analysis had been performed in most patients within
the scope of the diagnostic workup. If not, mutation analysis
of the NAGLU gene was performed in fibroblasts by standard
Sanger sequencing methods. Mutation nomenclature is ac-
cording the HGVS (http://www.hgvs.org/mutnomen/).
Sequence reference for the NAGLU gene is NM 000263.3.
Cell culture
Fibroblast cell lines were tested for mycoplasma contamination
and were subsequently cultured in Dulbecco’s Modified Eagle's
Medium supplementedwith 10% inactivated Fetal Bovine Serum
(FBS) and 100 U/mL penicillin, 100 μg/mL streptomycin, and
250 μg/mL amphotericin in a humidified atmosphere containing
5 % CO2. To remove bovine NAGLU in the FBS, NAGLU was
inactivated by incubation of FBS at 65 °C for 35 minutes.
Fibroblasts were plated at 70 % confluence and cultured at
a temperature of either 37 °C or 30 °C for 7 days. After a week
the medium was removed and cell layers were washed twice
with phosphate buffered saline (PBS). After harvesting, cell
pellets were washed once with PBS and twice with 0.9 %
NaCl and stored at −20 °C until further analysis.
Enzymatic activity of NAGLU in fibroblasts
NAGLU activity in fibroblasts was measured using the
fluorogenic substrate 4-methylumbelliferyl-2-acetamido-2-
deoxy -α -D-g lucopyranos ide (4MU-α -G lcNAc)
(Moscerdam, Oegstgeest, The Netherlands) using a modified
version of the method described by Marsh and Fensom
(Marsh and Fensom 1985). The 4MU-α-GlcNAc substrate
was dissolved to a concentration of 6 mg/mL in 0.1 M citrate
0.2 M phosphate buffer pH 4.3. Cell pellets were resuspended
in milliQ (Synergy® Water Purification System, Millipore,
Billerica, MA, USA) supplementedwith one cOmplete™ pro-
tease inhibitor cocktail tablet per 10 mL milliQ (Roche,
Mannheim, Germany). Cells were disrupted by sonification
uing a Vibra Cell sonicator (Sonics & Materials Inc.,
Newtown, CT, USA). Subsequently, protein concentration
was measured in whole cell lysates as described by Lowry et
al (Lowry et al 1951). For the determination of NAGLU ac-
tivity, cell lysates were diluted to a concentration of 1 mg/mL
and 30μL of cell lysate was added to 15μL 4MU-α- GlcNAc
solution and 15 μL of a 0.1 M citrate 0.2 M phosphate buffer
with pH 3.85. After 4 hours incubation at 37 °C, the reaction
was stopped with 1440 μL 0.2 M sodium carbonate 0.5 M
glycine buffer, pH 10.5. Released 4-methylumbelliferone was
measured fluorometrically with an excitation wavelength of
360 nm and emission wavelength of 450 nm using a Perkin
Elmer LS45 fluorescence spectrometer (Perkin Elmer,
Waltham, MA, USA). NAGLU activity in each sample was
calculated using a calibration curve of 4-methylumbelliferone
(Glycosynth Ltd., Warrington, Cheshire, UK). All enzyme
activity assays were performed in duplicate and repeated at
least once in independent fibroblast cultures.
HS analysis in fibroblasts
HS levels were determined as described previously (Kingma
et al 2013). HS in 25 μg of fibroblast lysate was enzymatically
digested into disaccharides. As a final deproteination step
samples were loaded on an Amicon Ultra 10 kD centrifugal
filter (EMDMillipore, Billerica,MA, USA) and centrifuged at
14,000 g for 30 minutes at a temperature of 25 °C.
Statistical analysis
All data analyses were performed using SPSS software for
Windows (version 21.0, SPSS Inc., Chicago, IL, USA). Non-
parametric statistical tests were used to analyze the relationship
betweenMPS IIIB phenotype and NAGLU activity levels after
cell culturing at 37 °C and 30 °C and the NAGLU activity ratio
after culturing at 30 °C over the activity after culturing at 37 °C,
respectively. Linear regression was performed to determine the
correlation between the ratio of NAGLU activity after cell cul-
turing at 30 °C over 37 °C and clinical signs of disease pro-
gression. Cut-off values of NAGLU activity that could discrim-
inate between MPS III phenotypes, were identified using re-
ceiver operating characteristic (ROC) curve analysis. True pos-
itive rates (sensitivity) were plotted against false positive rates
(1-specificity) for all classification points and p-values were
calculated for the area under the curve. A p-value of<0.05
was considered statistically significant.
Results
Patients
Twenty-eight patients from 17 different families were includ-
ed in this study (Table 1). Six patients were classified as RP
patients and 22 as SP patients. At the time of this study 15 out
of 28 patients were still alive. In the RP patients death oc-
curred at a younger age than in the SP patients (median age
14 years, range 13–20 years vs. median age 51 years, range
28–69 years, respectively. p< 0.001). RP patients lost their
ability to communicate in a meaningful way at a median age
of 6 years (range 5–10 years). In patients with the SP pheno-
type this was 24 years (range 8–69 years) (p<0.001). The
J Inherit Metab Dis (2016) 39:437–445 439
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median age at loss of the ability to walk independently was
14 years (range 8–18 years) in RP patients and 50 years (range
18–68 years) in the SP patients (p<0.001).
Mutations
For all patients mutations are presented in Table 1. All muta-
tions in our cohort have been reported previously, except the
missense mutation c.509G>A; p.(Gly170Asp) found in pa-
tient 15 (Zhao et al 1996; Beesley et al 1998; Schmidtchen et
al 1998; Weber et al 1999; Valstar et al 2010a).
NAGLU activity in fibroblasts after culturing at 37 °C
and 30 °C
To investigate whether residual enzyme activity in cultured skin
fibroblasts differentiates between RP and SP patients, NAGLU
activity in fibroblasts was measured. In Fig. 1a, NAGLU activ-
ity levels in fibroblasts of all individual MPS IIIB patients are
depicted after culturing at 37 °C and 30 °C. Very low levels of
NAGLU activity were observed for all patients after culturing
at 37 °C. Under these conditions fibroblasts from RP patients
showed a median enzymatic activity of 0.17 nmol.mg−1.hr−1
(range 0.14-0.23 nmol.mg−1.hr−1) compared to a median enzy-
matic activity of 0.27 nmol.mg−1.hr−1 (range 0.16-
3.84 nmol.mg−1.hr−1) in fibroblasts from SP patients. As is
shown in Fig. 1b, a small, though significant difference in
NAGLU activity between the RP and SP group was seen after
culturing at 37 °C (p<0.01). However, when looking at indi-
vidual values of enzymatic activity there is still considerable
overlap between the two groups. Figure 1c shows that culturing
fibroblasts at 30 °C for 1 week resulted in a more pronounced
difference in NAGLU activity between the two groups. After
culturing fibroblasts at 30 °C significantly higher NAGLU ac-
tivity levels were found in SP patients (median NAGLU activ-
ity 2.92 nmol.mg−1.hr−1 (range 0.66-13.70 nmol.mg−1.hr−1))
compared to RP patients (median NAGLU activity after cultur-
ing at 30 °C 0.30 nmol .mg−1 .hr−1 ( range 0.15-
0.50 nmol.mg−1.hr−1)) (p<0.001). ROC analysis showed an
area under the curve of 1.0, indicating that NAGLU activity
after culturing at 30 °C is a very accurate tool to discriminate
between RP and SP patients (p<0.001). A NAGLU activity of
0.58 nmol.mg−1.hr−1 was calculated to be the optimal cut-off
value to distinguish RP patients from SP patients with a sensi-
tivity and specificity of 100 % (Fig. 1d).
HS levels in fibroblasts
HS levels in RP and SP MPS IIIB patients’ fibroblasts were
analyzed to assess whether storage levels are influenced by the
differences in NAGLU activity levels observed between the
two groups. No significant difference was found in HS level
between the groups when fibroblasts were cultured at 37 °C
(Fig. 2). However, in fibroblasts cultured at 30 °C HS levels
were significantly lower in fibroblasts from patients with an SP
phenotype compared to fibroblasts from patients with an RP
phenotype (p<0.05). Culturing fibroblasts of RP patients at
either 37 °C or 30 °C, did not result in any significant differ-
ences in HS levels, while significantly lower HS levels after
culturing at 30 °C were found in patients within the SP group,
compared to levels after culturing at 37 °C (p<0.01). This
indicates that the increased NAGLU activity, measured in vitro
after culturing cells at 30 °C, indeed corresponds to higher
levels of functional NAGLU in fibroblasts of SP patients.
Disease symptoms and NAGLU activity ratio
after culturing at 30 °C over 37 °C
The capacity of patients’ fibroblasts to increase residual enzyme
activity was further assessed by calculating the ratio of NAGLU
activity after culturing at 30 °C over the activity after culturing at
37 °C. The ratio of NAGLU activity after culturing at 30 °C over
37 °C was 9.36 (range 1.93-31.49) in SP patients, which was
significantly higher compared to patients in the RP group, who
had a median ratio of NAGLU activity of 1.78 (range 0.96-2.39)
(p<0.001) (Fig. 3a). Because MPS IIIB comprises a continuous
spectrum of disease severity, we assessed whether this ratio cor-
related more specifically with the age at which patients lost spe-
cific functions. A lower capacity of patients’ fibroblasts to in-
crease NAGLU activity at 30 °C could significantly predict for
the loss of the ability to communicate verbally in a meaningful
manner and the loss of the ability to walk independently at a
younger age (Fig. 3b and c). Also, the age of demise correlated
with the NAGLU activity ratio after culturing at 30 °C over the
activity after culturing at 37 °C (Fig. 3d).
Discussion
Over recent years, a number of studies on potential disease
modifying treatment options for MPS IIIB have been initiated.
For evaluating clinical efficacy as well as for assessing which
patients may benefit the most from a specific treatment, it will
be essential to predict the natural course of the disease for each
individual patient at an early stage. Here, we investigate an
approach to discriminate between MPS IIIB patients with a
rapidly progressing (RP, classical or severe) phenotype and
patients with a slowly progressing (SP, attenuated) phenotype,
using cultured skin fibroblasts.
We observed a significant difference in residual activity of
NAGLU between fibroblasts from RP and SP patients when
fibroblasts were cultured at 37 °C. However, NAGLU activity
did not completely discriminate between the two groups.
Culturing fibroblasts at 30 °C, however, allowed for complete
separation between RP and SP patients. Accordingly, HS levels
after culturing at 30 °C were significantly lower in fibroblasts
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Fig. 1 a. Mean NAGLU activity (nmol.mg−1.hr−1) of duplicate
measurement in fibroblasts of the individual MPS IIIB patients after
culturing cells at 37 °C and 30 °C for 1 week. Patient numbers
correspond with the numbers in Table 1. Data of one representative ex-
periment are shown. b and c. NAGLU activity (nmol.mg−1.hr−1) mea-
sured in fibroblasts of SP and RPMPS IIIB patients after culturing cells at
37 °C and 30 °C for 1 week, respectively. Medians are given. Data of one
representative experiment are shown. d. Sensitivity and specificity for
cut-off levels of NAGLU activity in fibroblasts after culturing at 30 °C
to distinguish between RP and SP MPS IIIB patients. The dashed line
indicates the calculated optimal cut-off level of 0.58 nmol.mg−1.hr−1
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from the SP group than in fibroblasts from the RP group. This
indicates that the increased NAGLU activity measured in pro-
tein lysates after culture at 30 °C comprises a form of the en-
zyme that is biochemically active in living cells and exerts its
catalytic function in the lysosome. Nevertheless, it should be
taken into consideration that other factors, such as alteration of
GAG synthesis, are responsible for lower HS levels. However,
it is unlikely that this only affects the SP group.
MPS IIIB is characterized by a large genetic heterogeneity
which is probably the most important cause of the phenotypic
variability. Although some genotype-phenotype correlations
have been established in MPS IIIB, previously unrecognized
mutations are frequently reported. In our limited series of pa-
tients, the RP patients all have two nonsense or frameshift
mutations, whereas all the SP patients have at least one mis-
sense mutation. Irrespectively of genotype, NAGLU activity
in fibroblasts after culturing at 30 °C appears to reliably pre-
dict for an RP or SP phenotype.
MPS IIIB comprises a continuous spectrum of disease
severity, and a division in only an RP and an SP group
does no justice to the clinical variability observed in pa-
tients. Valstar et al showed that the loss to communicate
in a meaningful manner and the ability to walk indepen-
dently are key symptoms in the assessment of disease
progression (Valstar et al 2010a). We therefore correlated
the loss of these functions to the ratio of NAGLU activity
at 30 °C over 37 °C. The capacity of fibroblasts to en-
hance residual enzyme activity at 30 °C correlated with
the course of the disease. However, since not all patients
had already reached these stages of disease, patient num-
bers are small and more patients would be needed to val-
idate these correlations.
The increased levels of residual NAGLU measured in
SP patients after culturing cells at 30 °C, might be due to
more efficient protein folding at this lower temperature,
thereby stimulating the activity of mutant enzymes
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cFig. 3 a. Ratio of NAGLU
activity after culturing at 30 °C
over the activity after culturing at
37 °C measured in fibroblasts of
SP and RP MPS IIIB patients.
Medians are given. Data of one
representative experiment are
shown. b-d. Ratio of NAGLU
activity after culturing at 30 °C
over the activity after culturing at
37 °C in fibroblasts, correlated to
the age of speech loss (23 out of
28 patients), to the age of loss of
mobility (19 out of 28 patients),
and correlated to the age of
demise (13 out of 28 patients who
had died at time of this study).
Data of one representative
experiment are shown
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(Gootjes et al 2004; Diekman et al 2015). The positive
effect of culturing human fibroblasts at 30 °C on protein
quantity and enzymatic activity has already been demon-
strated for a distinct metabolic disorder by another group
in our lab (Houten et al 2002). Cells of patients with a
mild mevalonate kinase deficiency showed higher enzy-
matic activity after culturing at 30 °C which correlated
with higher protein levels on Western blot. Culture tem-
perature had no effect on cells of patients with a severe
mevalonate kinase deficiency. We hypothesize that the
higher levels of NAGLU activity found in SP patients
might be caused by the presence of molecular chaperones
or differences in the regulation of the endoplasmic-
reticulum-associated protein degradation machinery which
only become apparent at 30 °C culture conditions, at least
in the in vitro setting.
In most SP fibroblasts, culturing at 30 °C resulted in levels
of NAGLU activity that exceeded 10 % of control enzyme
activity (reference values for NAGLU activity in fibroblasts
used in our diagnostic laboratory are 9–17 nmol.mg−1.hr−1).
Ten percent of control NAGLU activity is often associated
with the amelioration of symptoms. Our findings indicate that
residual NAGLU activity can potentially be enhanced and that
MPS IIIB patients with a SP phenotype might benefit from
therapies that interfere with protein folding, such as chemical
and pharmacological chaperones (Meijer et al 2013).
However, more research is needed to elucidate the underlying
processes and the effects of therapies that interfere with these
mechanisms.
To be able to measure low levels of NAGLU activity
and to detect minor changes in enzyme activity at different
conditions in all patient cell lines, we optimized the assay
normally used in our diagnostic department. Using this
optimized assay, in patient 25 remarkably high levels of
NAGLU activity and low HS levels were found at all cul-
ture conditions, despite previous genetic and biochemical
confirmation of the diagnosis MPS IIIB. The use of high
concentrations of 4MU-α-G1cNAc substrate (1.5 mg/mL
final concentration) in combination with an optimized pH
and incubation time, might have favored the particular ki-
netic properties of the mutant enzyme in this patient.
Furthermore, NAGLU with this particular mutation might
have an increased affinity to the 4MU-substrate, as com-
pared to natural substrates present in vivo. This is currently
being further investigated.
In conclusion, we show that NAGLU activity in fibroblasts
cultured at 30 °C can be used to discriminate between RP and
SP MPS IIIB patients and that the capacity of cells to increase
NAGLU activity at lower temperatures correlates with disease
severity and progression. Prediction of the phenotype of an
individual patient may become of high relevance in the near
future for assessment of the efficacy of disease modifying
treatments for MPS IIIB.
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